Fresenius Kabi in talks to buy Akorn

By Gareth Macdonald contact

- Last updated on GMT

iStock/macgyverhh
iStock/macgyverhh

Related tags: U.s. securities and exchange commission, Fresenius kabi

Akorn Inc is in takeover talks with German injectable drug specialist Fresenius SE & Co. KGaA.

The US generic drug manufacturer confirmed the talks in a US Securities and Exchange Commission (SEC) filing​ today.

Similarly, Fresenius said​ discussions are ongoing.

A spokesman for the German firm told us "Fresenius Kabi is currently in discussions with Akorn, Inc. concerning a potential acquisition​."

He declined to comment further.

Related news

Show more

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us

Products

View more

Webinars